quinacrine has been researched along with hydroxychloroquine in 62 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 29 (46.77) | 18.7374 |
1990's | 6 (9.68) | 18.2507 |
2000's | 9 (14.52) | 29.6817 |
2010's | 14 (22.58) | 24.3611 |
2020's | 4 (6.45) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chellappan, DK; Collet, TA; Dighe, SN; Dua, K; Ekwudu, O; Katavic, PL | 1 |
He, E; Xiao, R; Zeng, R; Zhang, A; Zhao, J | 1 |
Lanciani, P | 1 |
Bell, AL; Betts, WH; Cleland, LG; French, JK; Hurst, NP; Nuki, G; O'Donnell, ML | 1 |
Franks, A; Werth, V | 1 |
Clark, SK | 1 |
Boström, H; Whitehouse, MW | 1 |
Cowey, FK; Whitehouse, MW | 1 |
Brown, RK | 1 |
Ball, EG; Markus, HB | 1 |
Dodge, BG; Freeman, RG; Knox, JM | 1 |
Carr, RE; Henkind, P; Rothfield, N; Siegel, IM | 1 |
Elslager, EF; Tendick, FH; Werbel, LM | 1 |
Koranda, FC | 1 |
Hughes, GR; Lanham, JG | 1 |
Elgart, M; Isaacson, D; Turner, ML | 1 |
Tanenbaum, L; Tuffanelli, DL | 1 |
Olansky, AJ | 1 |
Cox, NH; Paterson, WD | 1 |
Feldmann, R; Salomon, D; Saurat, JH | 1 |
Wallace, DJ | 1 |
Mehregan, DR; Su, WP | 1 |
Rynes, RI | 1 |
Chung, HS; Hann, SK | 1 |
Golan, TD; Kessel, A; Rosner, I; Rozenbaum, M; Toubi, E | 1 |
Cohen, JB | 1 |
Golan, TD; Kessel, A; Lorber, M; Paran, D; Rosner, I; Rozenbaum, M; Sabo, E; Toubi, E | 1 |
ANSELL, HB; APPEL, B; SCHIFF, B; TYE, MJ; WOLF, M | 1 |
ANSELL, HB; APPEL, B; TYE, MJ; WHITE, H | 1 |
FREDRIKSSON, T; LODIN, A; ROSENGREN, S | 1 |
ABRAHAM, RK; DUBOIS, EI; TUFFANELLI, D | 1 |
CAHN, MM; LEVY, EJ; SHAFFER, B | 1 |
ARORA, RB; LAL, A | 1 |
BORC, K | 1 |
BOUMA, HG; DEVRIES, K; JANSZ, A; NIEWEG, HO | 1 |
SULLI, G; VARRONE, F | 1 |
BOTTIROLI, JA; ROSENBERG, FJ | 1 |
ALVING, AS; BREWER, GJ; MILLAR, JW; POWELL, RD | 1 |
RUTLEDGE, WU | 1 |
BETTLEY, FR | 1 |
Geraminejad, P; Sontheimer, RD; Stone, MS | 1 |
Tutor-Ureta, P; Yebra-Bango, M | 1 |
Iczkowski, KA; Kelly, BJ; Mrstik, ME; Ramos-Caro, FA | 1 |
Kessel, A; Paran, D; Rosner, I; Rozenbaum, M; Shoenfeld, Y; Toubi, E | 1 |
Bazzani, C; Calzavara-Pinton, PG; Cattaneo, R; Cavazzana, I; Ceribelli, A; Franceschini, F; Sala, R; Tincani, A; Zane, C | 1 |
Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ | 1 |
Chang, AY; Foering, KP; Okawa, J; Piette, EW; Tenhave, TR; Werth, VP | 1 |
Chang, AY; Feng, R; Foering, KP; Okawa, J; Piette, EW; Ten Have, TR; Werth, VP | 1 |
Callen, JP | 1 |
Gonzalez-Rivera, T; McCune, WJ | 1 |
Bakardzhiev, I; Chokoeva, AA; Krasnaliev, I; Lotti, T; Tana, C; Tchernev, G; Wollina, U | 1 |
Kahlenberg, JM; Stannard, JN | 1 |
Marceau, F; Parks, A | 1 |
Alves, P; Bashir, MM; Feng, R; Werth, VP; Wysocka, M; Zeidi, M | 1 |
Agesta, N; Martinez-Zapico, A; Ortego-Centeno, N; Porta, S; Ríos, R; Ruiz-Irastorza, G; Ugarte, A | 1 |
Danza, A; Ruiz-Irastorza, G; Ugarte, A | 1 |
Chansky, PB; Werth, VP; Zeidi, M | 1 |
Kim, HJ; Werth, VP; Zeidi, M | 1 |
Birring, S; Brex, P; Galloway, J; Larkin, G; Murgatroyd, F; Paolino, A; Patel, A; Sado, D; Walsh, S | 1 |
Chakka, S; Chen, KL; Desai, K; Kim, HJ; Lim, R; Patel, J; Werth, VP; Zeidi, M | 1 |
Chin, F; Dan, J; Diaz, D; Feng, R; Grinnell, M; Keyes, E; Li, Y; Patel, J; Sharma, M; Sprow, G; Vazquez, T; Werth, VP; Yan, D | 1 |
12 review(s) available for quinacrine and hydroxychloroquine
Article | Year |
---|---|
Recent update on anti-dengue drug discovery.
Topics: Animals; Antiviral Agents; Biological Products; Cell Line, Tumor; Dengue Virus; Drug Discovery; Humans; Serine Proteinase Inhibitors; Viral Nonstructural Proteins; Virus Replication | 2019 |
Small molecules targeting cGAS-STING pathway for autoimmune disease.
Topics: Autoimmune Diseases; Humans; Inflammation; Membrane Proteins; Nucleotidyltransferases; Signal Transduction | 2022 |
Antimalarials.
Topics: Antimalarials; Chloroquine; DNA; Eye Diseases; Humans; Hydroxychloroquine; Quinacrine; RNA; Skin Diseases | 1981 |
Antimalarial therapy in SLE.
Topics: Antimalarials; Binding Sites; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Immune Tolerance; Inflammation; Kinetics; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Nucleoproteins; Photosensitivity Disorders; Pregnancy; Quinacrine; Retinal Diseases; Retinal Pigments; Skin Diseases; Virus Replication | 1982 |
Anti-malarials in dermatology.
Topics: Absorption; Amodiaquine; Antimalarials; Chemical Phenomena; Chemistry; Chloroquine; Female; Humans; Hydroxychloroquine; Quinacrine; Skin Diseases | 1982 |
Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Chloroquine; DNA; Eye Diseases; Female; Hematologic Diseases; Humans; Hydroxychloroquine; Immunosuppressive Agents; Male; Melanins; Neuromuscular Diseases; Porphyrias; Pregnancy; Quinacrine; Skin; Sunscreening Agents | 1980 |
Antimalarials and ophthalmologic safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine; Retinal Diseases | 1982 |
Antimalarial agents and lupus.
Topics: Antibodies, Antiphospholipid; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Kidney Diseases; Lupus Erythematosus, Systemic; Neuromuscular Diseases; Pregnancy; Quinacrine | 1994 |
Antimalarial drugs in the treatment of rheumatological diseases.
Topics: Antimalarials; Chloroquine; Contraindications; Female; Humans; Hydroxychloroquine; Male; Pregnancy; Pregnancy Complications; Quinacrine; Rheumatic Diseases; Skin | 1997 |
[EXTRAMALARIAL THERAPUETIC APPLICATIONS OF ANTIMALARIAL DRUGS. 1. CLINICAL UTILIZATIONS].
Topics: Amodiaquine; Antimalarials; Chloroquine; Collagen Diseases; Dermatology; Drug Utilization; Epilepsy; Female; Heart Diseases; Hematology; Humans; Hydroxychloroquine; Hypersensitivity; Multiple Sclerosis; Muscular Diseases; Neurology; Parasitic Diseases; Pharmacology; Primaquine; Proguanil; Pyrimethamine; Quinacrine; Quinine; Toxicology; Uterus | 1963 |
Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimalarials; Autoantibodies; CTLA-4 Antigen; Cytokines; Dapsone; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; HLA Antigens; Humans; Hydroxychloroquine; Interferon Regulatory Factors; Interferon Type I; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Quinacrine; Sunscreening Agents; Tumor Necrosis Factor-alpha; TYK2 Kinase; Ultraviolet Rays | 2016 |
Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions.
Topics: Antimalarials; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Methylprednisolone; Prednisone; Quinacrine; Treatment Outcome | 2018 |
3 trial(s) available for quinacrine and hydroxychloroquine
Article | Year |
---|---|
The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients.
Topics: Adult; Antimalarials; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Quinacrine; Time Factors | 2000 |
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Antimalarials; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Prednisone; Quinacrine; Severity of Illness Index | 2003 |
The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Topics: Adult; Antibodies, Anticardiolipin; Antirheumatic Agents; Azathioprine; B-Cell Activating Factor; Case-Control Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Membrane Proteins; Middle Aged; Prednisolone; Quinacrine; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2006 |
47 other study(ies) available for quinacrine and hydroxychloroquine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
[Synthetic antimalarials in the therapy of rheumatoid arthritis: adverse effects and advantages].
Topics: Arthritis, Rheumatoid; Chloroquine; Drug Evaluation; Enzyme Inhibitors; Histamine H1 Antagonists; Humans; Hydroxychloroquine; Quinacrine; Time Factors | 1985 |
Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes.
Topics: Arachidonic Acid; Arachidonic Acids; Calcimycin; Cell Survival; Chloroquine; Fluorides; Humans; Hydroxychloroquine; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Phospholipids; Quinacrine; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 1986 |
Treatment of discoid skin lesions with azathioprine.
Topics: Azathioprine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Quinacrine | 1986 |
Cutaneous lupus erythematosus. Recognition of its many forms.
Topics: Adrenal Cortex Hormones; Adult; Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Male; Quinacrine; Sex Factors; Skin; Skin Diseases | 1986 |
Biochemical properties of anti-inflammatory drugs. VI. The effects of chloroquine (resochin), mepacrine (quinacrine) and some of their potential metabolites on cartilage metabolism and oxidative phosphorylation.
Topics: Animals; Cartilage; Chloroquine; Glycosaminoglycans; Gold; Hydroxychloroquine; In Vitro Techniques; Indomethacin; Oxidative Phosphorylation; Polysaccharides; Quinacrine; Quinolines; Rats; Sulfates; Sulfur Isotopes; Thiosulfates | 1965 |
Biochemical properties of anti-inflammatory drugs. VII. Inhibition of proteolytic enzymes in connective tissue by chloroquine (resochin) and related antimalarial antirheumatic drugs.
Topics: Acridines; Animals; Cartilage; Cattle; Chloroquine; Chondroitin; Connective Tissue; Hyaluronoglucosaminidase; Hydrogen-Ion Concentration; Hydroxychloroquine; Microbial Collagenase; Mucoproteins; Papain; Primaquine; Quaternary Ammonium Compounds; Quinacrine; Rabbits | 1966 |
Discoid lupus erythematosus.
Topics: Adult; Antimalarials; Chloroquine; Color Vision Defects; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Quinacrine; Retinal Diseases | 1972 |
Inhibition of lipolytic processes in rat adipose tissue by antimalaria drugs.
Topics: Adipose Tissue; Animals; Antimalarials; Chloroquine; Epididymis; Fatty Acids; Heparin; Hydroxychloroquine; Lipid Metabolism; Male; Primaquine; Quinacrine; Quinidine; Quinine; Rats | 1969 |
Erythema dyschromicum perstans.
Topics: Adolescent; Adult; Biopsy; Blood Cell Count; Blood Sedimentation; Child, Preschool; Chloroquine; Erythema; Feces; Female; Humans; Hydroquinones; Hydroxychloroquine; Male; Middle Aged; Parasitic Diseases; Prednisone; Quinacrine; Steroids; Syphilis Serodiagnosis; Triamcinolone | 1968 |
Ocular toxicity of antimalarial drugs. Long-term follow-up.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Electrooculography; Electroretinography; Eye Diseases; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychloroquine; Light; Lupus Erythematosus, Systemic; Macula Lutea; Middle Aged; Ophthalmoscopy; Quinacrine; Retinitis; Vision Tests; Visual Fields | 1968 |
Repository drugs. 8. Ester and amide congeners of amodiaquine, hydroxychloroquine, oxychloroquine, primaquine, quinacrine, and related substances as potential long-acting antimalarial agents.
Topics: Amodiaquine; Animals; Antimalarials; Chemical Phenomena; Chemistry; Delayed-Action Preparations; Esters; Hydroxychloroquine; Malaria; Mice; Primaquine; Quinacrine | 1969 |
Ocular toxicity of antimalarials in dermatology: a survey of current practice.
Topics: Antimalarials; Dermatology; Drug Administration Schedule; Humans; Hydroxychloroquine; Quinacrine; Referral and Consultation; Retinal Diseases; Risk Factors; Skin Diseases; Time Factors | 1994 |
The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Topics: Adult; Aged; Chloroquine; Drug Combinations; Drug Tolerance; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Male; Middle Aged; Quinacrine; Vision Disorders | 1994 |
Cyclosporine treatment for dermatomyositis/polymyositis.
Topics: Azathioprine; Cyclosporine; Dermatomyositis; Female; Humans; Hydroxychloroquine; Middle Aged; Polymyositis; Prednisone; Quinacrine | 1993 |
Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine.
Topics: Adult; Antimalarials; Antirheumatic Agents; Drug Therapy, Combination; Humans; Hydroxychloroquine; Male; Panniculitis, Lupus Erythematosus; Quinacrine | 1997 |
Cutaneous involvement of dermatomyositis can respond to Dapsone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Dapsone; Dermatomyositis; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Prednisone; Quinacrine | 2002 |
Treatment of chronic lupus erythematosus: effectiveness of plaquenil and APA (Aralen 65 mg., plaquenil 50 mg., Atabrine 25 mg.) as compared with Aralen, with observations on side-reactions and toxicity; report and presentation of unusual cases.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1958 |
Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1959 |
[Treatment of discoid lupus erythematosus, polymorphous photodermatosis and rosacea with Triquin--a combination of 3 anti-malarials].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Photosensitivity Disorders; Quinacrine; Rosacea | 1962 |
PIGMENTATION FROM ANTIMALARIAL THERAPY. ITS POSSIBLE RELATIONSHIP TO THE OCULAR LESIONS.
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Cornea; Eye; Eye Manifestations; Histocytochemistry; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Photomicrography; Pigmentation; Pigmentation Disorders; Quinacrine; Retina; Toxicology | 1963 |
POLYMORPHOUS LIGHT ERUPTION. A TEN-YEAR FOLLOW-UP AND EVALUATION.
Topics: Chloroquine; Dermatitis, Phototoxic; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Photosensitivity Disorders; Prurigo; Quinacrine; Seasons; Sunlight | 1963 |
ANTIMALARIAL DRUGS ON THE AUTOMATICITY OF SINO-AURICULAR AND ATRIO-VENTRICULAR NODES.
Topics: Administration, Intravenous; Amodiaquine; Animals; Anti-Arrhythmia Agents; Antimalarials; Atrioventricular Node; Atropine; Chloroquine; Dogs; Heart Conduction System; Humans; Hydroxychloroquine; Hypotension; Injections, Intravenous; Primaquine; Quinacrine; Quinidine; Research; Statistics as Topic | 1963 |
[CHRONIC DISCOID ERYTHEMATOSUS (REPORT ON 69 CASES OVER A PERIOD OF 6 YEARS FROM THE VIEWPOINT OF OPTIMUM THERAPY)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1963 |
HAEMATOLOGICAL SIDE-EFFECTS OF SOME ANTI-RHEUMATIC DRUGS.
Topics: Aminopyrine; Antirheumatic Agents; Aspirin; Blood Platelets; Chloroquine; Colchicine; Complement Fixation Tests; Drug Hypersensitivity; Gold; Humans; Hydroxychloroquine; Meprobamate; Phenacetin; Phenylbutazone; Probenecid; Purpura; Purpura, Thrombocytopenic; Quinacrine; Rheumatic Diseases; Splenectomy; Toxicology | 1963 |
ANTIMALARIALS AND OTHER ANTICONVULSANT DRUGS: PREDICTIVE VALIDITY OF LABORATORY TESTS.
Topics: Animals; Anticonvulsants; Antimalarials; Chloroquine; Electric Stimulation; Hydroxychloroquine; Mice; Pentylenetetrazole; Pharmacology; Phenobarbital; Phenytoin; Quinacrine; Research; Seizures | 1964 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND.
Topics: Amodiaquine; Antimalarials; Asia, Southeastern; Biomedical Research; Chloroquine; Drug Resistance; Drug Resistance, Microbial; Humans; Hydroxychloroquine; Malaria; Malaria, Falciparum; Pharmacology; Plasmodium falciparum; Proguanil; Pyrimethamine; Quinacrine; Quinine; Thailand | 1964 |
WHAT'S NEW AND WHAT'S TRUE OF WHAT'S NEW IN DERMATOLOGY.
Topics: Amodiaquine; Dermatology; Humans; Hydroxychloroquine; Keratoacanthoma; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Psoriasis; Quinacrine; Quinine; Steroids; Toxicology | 1964 |
CHILBLAIN LUPUS ERYTHEMATOSUS.
Topics: Chilblains; Chloroquine; Fluocinolone Acetonide; Frostbite; Humans; Hydroxychloroquine; Hypothyroidism; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Niacinamide; Quinacrine; Telangiectasis; Triamcinolone | 1964 |
Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus.
Topics: Antimalarials; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lichenoid Eruptions; Lupus Erythematosus, Cutaneous; Middle Aged; Quinacrine | 2004 |
[Systemic lupus erythematosus therapy. Antimalarials in inflammatory diseases].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Quinacrine | 2004 |
Papular elastolytic giant cell granuloma responding to hydroxychloroquine and quinacrine.
Topics: Aged; Dermatologic Agents; Elastic Tissue; Exanthema; Giant Cells; Granuloma, Giant Cell; Humans; Hydroxychloroquine; Lymphocytes; Male; Quinacrine; Skin Diseases, Papulosquamous; Treatment Outcome | 2004 |
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Topics: Adult; Antimalarials; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Middle Aged; Quinacrine; Retrospective Studies; Skin; Treatment Outcome | 2009 |
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Kidney Transplantation; Lupus Erythematosus, Systemic; Metaplasia; Nephrogenic Fibrosing Dermopathy; Pregabalin; Quinacrine; Skin; Thalidomide; Treatment Outcome | 2010 |
Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
Topics: Adolescent; Adult; Aged; Antimalarials; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Longitudinal Studies; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Prospective Studies; Quinacrine; Severity of Illness Index; Treatment Outcome; Young Adult | 2011 |
Impact of smoking in cutaneous lupus erythematosus.
Topics: Adult; Antimalarials; Cohort Studies; Comorbidity; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunologic Factors; Longitudinal Studies; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Prospective Studies; Quality of Life; Quinacrine; Smoking; Young Adult | 2012 |
Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
Topics: Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Male; Quinacrine | 2011 |
Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?
Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eye Diseases; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Quinacrine; Remission Induction; Time Factors | 2015 |
Unilateral unique Lupus tumidus: pathogenetic mystery and diagnostic problem.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Biopsy; Chloroquine; Combined Modality Therapy; Dapsone; Diagnosis, Differential; Humans; Hydroxychloroquine; Lasers, Dye; Lupus Erythematosus, Discoid; Male; Ointments; Quinacrine; Skin; Sunscreening Agents; Tacrolimus | 2016 |
Lysosomotropic cationic drugs induce cytostatic and cytotoxic effects: Role of liposolubility and autophagic flux and antagonism by cholesterol ablation.
Topics: Amiodarone; Anticholesteremic Agents; Autophagy; beta-Cyclodextrins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chloroquine; Cholesterol; Cytostatic Agents; Cytotoxins; Human Umbilical Vein Endothelial Cells; Humans; Hydroxychloroquine; Lidocaine; Lovastatin; Lysosomes; Microtubule-Associated Proteins; Poly (ADP-Ribose) Polymerase-1; Procainamide; Quinacrine | 2016 |
Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.
Topics: Antimalarials; Cells, Cultured; Dendritic Cells; Dermatomyositis; Drug Interactions; Humans; Hydroxychloroquine; Interferon-alpha; Leukocytes, Mononuclear; Lipopolysaccharides; Lupus Erythematosus, Cutaneous; Monocytes; Quinacrine; Tumor Necrosis Factor-alpha | 2017 |
Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Topics: Adult; Antimalarials; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Joint Diseases; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Male; Middle Aged; Quinacrine; Remission Induction; Retrospective Studies; Smokers; Treatment Outcome | 2018 |
Acute onset/flares of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings.
Topics: Acute Disease; Autoantibodies; Autoimmune Diseases; Dermatomyositis; Dietary Supplements; Humans; Hydroxychloroquine; Interferon-alpha; Interferon-beta; Leukocytes, Mononuclear; Lipopolysaccharides; Primary Cell Culture; Quinacrine; Symptom Flare Up; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2019 |
Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
Topics: Adult; Antimalarials; Dendritic Cells; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Quinacrine; Skin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2019 |
Clinical phenotypes and therapeutic responses in cutaneous-predominant sarcoidosis: 6-year experience in a tertiary referral service.
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Clinical Protocols; Dermatologic Agents; Female; Humans; Hydroxychloroquine; Interleukin-12; Interleukin-23; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Phenotype; Prospective Studies; Quinacrine; Referral and Consultation; Remission Induction; Sarcoidosis; Skin Diseases; Tertiary Care Centers; Tumor Necrosis Factor Inhibitors; Young Adult | 2021 |
Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antimalarials; Female; Fluorescent Antibody Technique; Humans; Hydroxychloroquine; Immunohistochemistry; Lectins, C-Type; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Quinacrine; Receptors, CCR7; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; T-Lymphocytes; Treatment Outcome | 2022 |
Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus In Vivo Stratified by Patient Response to Antimalarials.
Topics: Antimalarials; Granzymes; Humans; Hydroxychloroquine; Immunosuppressive Agents; Interferon Regulatory Factor-3; Interferons; Interleukin-17; Interleukin-4; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Quinacrine | 2022 |